首页> 外文期刊>Antimicrobial agents and chemotherapy. >Disposition of artesunate and dihydroartemisinin after administration of artesunate suppositories in children from Papua New Guinea with uncomplicated malaria.
【24h】

Disposition of artesunate and dihydroartemisinin after administration of artesunate suppositories in children from Papua New Guinea with uncomplicated malaria.

机译:巴布亚新几内亚患有单纯性疟疾儿童的青蒿琥酯栓剂给药后,青蒿琥酯和双氢青蒿素的处置。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

A detailed pharmacokinetic analysis was performed with 47 children from Papua New Guinea with uncomplicated falciparum or vivax malaria treated with artesunate (ARTS) suppositories (Rectocaps) given in two doses of approximately 13 mg/kg of body weight 12 h apart. Following an intensive sampling protocol, samples were assayed for ARTS and its primary active metabolite, dihydroartemisinin (DHA), by liquid chromatography-mass spectrometry. A population pharmacokinetic model was developed to describe the data. Following administration of the first dose, the mean maximal concentrations of ARTS and DHA were 1,085 nmol/liter at 0.9 h and 2,525 nmol/liter at 2.3 h, respectively. The absorption half-life for ARTS was 2.3 h, and the conversion half-life (ARTS to DHA) was 0.27 h, while the elimination half-life of DHA was 0.71 h. The mean common volumes of distribution for ARTS and DHA relative to bioavailability were 42.8 and 2.04 liters/kg, respectively, and the mean clearance values relative to bioavailability were 6 and 2.2 liters/h/kg for ARTS and DHA, respectively. Substantial interpatient variability was observed, and the bioavailability of the second dose relative to that of the first was estimated to be 0.72. The covariates age, sex, and alpha-thalassemia genotype were not influential in the pharmacokinetic model development; but the inclusion of weight as a covariate significantly improved the performance of the model. An ARTS suppositories dose of 10 of 20 mg/kg is appropriate for use in children with uncomplicated malaria.
机译:对来自巴布亚新几内亚的47名儿童进行了详细的药代动力学分析,他们接受了青蒿琥酯(ARTS)栓剂(Rectocaps)治疗的单纯性恶性疟或间日疟,分两次服用,剂量约13 mg / kg体重,间隔12 h。按照大量采样方案,通过液相色谱-质谱法分析样品中的ARTS及其主要活性代谢物二氢青蒿素(DHA)。建立了群体药代动力学模型来描述数据。首次给药后,ARTS和DHA的平均最大浓度在0.9小时时为1,085 nmol /升,在2.3小时时为2,525 nmol /升。 ARTS的吸收半衰期为2.3 h,转化半衰期(ARTS到DHA)为0.27 h,而DHA的消除半衰期为0.71 h。相对于生物利用度,ARTS和DHA的平均平均分配体积分别为42.8和2.04升/ kg,相对于生物利用度,ARTS和DHA的平均清除率分别为6和2.2升/ h / kg。观察到患者之间存在较大差异,第二剂相对于第一剂的生物利用度估计为0.72。年龄,性别和α地中海贫血基因型的协变量对药代动力学模型的发展没有影响;但是将权重作为协变量包括在内可以显着改善模型的性能。 ARTS栓剂的剂量为10 mg / kg,20 mg / kg,适合患有单纯性疟疾的儿童。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号